

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.80

1.43

FILE 'CAPLUS' ENTERED AT 14:27:15 ON 27 JUN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Jun 2003 VOL 138 ISS 26

FILE LAST UPDATED: 25 Jun 2003 (20030625/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 12

L3 2 L2

=> d bib abs 1-2

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS

AN 2002:54472 CAPLUS

DN 136:256738

TI Cyclohexylmethylpiperidinyltriphenylpropioamide: a selective muscarinic M3 antagonist discriminating against the other receptor subtypes

AU Sagara, Yufu; Sagara, Takeshi; Mase, Toshiaki; Kimura, Toshifumi; Numazawa, Tomoshige; Fujikawa, Toru; Noguchi, Kazuhito; Ohtake, Norikazu

CS Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories, Tsukuba, Ibaraki, 300-2611, Japan

SO Journal of Medicinal Chemistry (2002), 45(4), 984-987


CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

GI



AB To discover a highly selective M3 antagonist, a combinatorial library was prepd. The library was designed to identify a novel structural class of M3 antagonists by exploring the spatial arrangement of the pharmacophores

in known M3 antagonists. After the evaluation of 1000 library members, a potent M3 antagonist, (I) ($K_i = 0.31 \text{ nM}$), with novel structural features was identified. Compd. I showed high selectivity for M3 receptors over the other muscarinic receptor subtypes ($M1/M3 = 380\text{-fold}$, $M2/M3 = 98\text{-fold}$, $M4/M3 = 45\text{-fold}$, $M5/M3 = 120\text{-fold}$).

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

AN 2001:78358 CAPLUS

DN 134:147498

TI Preparation of amide derivatives as selective muscarinic M3 antagonists

IN Sagara, Yufu; Uchiyama, Minaho; Naya, Akira; Kimura, Toshifumi; Numazawa, Tomoshige; Fujikawa, Toru; Otake, Norikazu; Noguchi, Kazuhito

PA Banyu Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 187 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2001007406 | A1 | 20010201 | WO 2000-JP4762 | 20000714 |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: | | | | |
| | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1213281 | A1 | 20020612 | EP 2000-946352 | 20000714 |
| | R: | | | | |
| | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| PRAI | JP 1999-209292 | A | 19990723 | | |
| | JP 1999-338617 | A | 19991129 | | |
| | WO 2000-JP4762 | W | 20000714 | | |

OS MARPAT 134:147498

AB The title compds. $\text{Ar1C(Ar2)(Ar3)CHR1CON(R2)CHR3(CH2)pXY(R4)CHR5(CH2)mCONH(CH2)nA}$ [A is piperidine moiety (generic structure given), etc.; Ar1, Ar2 and Ar3 are each optionally substituted phenyl; p is 0 or 1; m, n are each 0, 1 or 2; R1 is hydrogen or optionally substituted lower alkyl; R2, R3, R4 and R5 are each hydrogen, optionally substituted lower alkyl, or the like; X is carbonyl or methylene; Y is nitrogen or methine] are prepd. The title compds. are useful as remedies for respiratory, urol. or digestive diseases. In in vitro tests for M3 antagonism, compds. of this invention showed the K_i values of 1.3 nM to 4.7 nM; in in vitro tests for M1 and M2 antagonism, said compds. showed the K_i values of 110 nM to > 2500 nM.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> activate cc31716/a


L1 STR

L2 55 SEA FILE=REGISTRY SSS FUL L1

=> d l1

L1 HAS NO ANSWERS

L1 STR



VAR G1=10/11/15

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

GGCAT IS MCY AT 1

GGCAT IS MCY AT 18

GGCAT IS MCY AT 19

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 10

NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE

=> d scan l1


L1 HAS NO ANSWERS

=> d scan l2

L2 55 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Benzenepropanamide, N-[6-oxo-6-[[[1-(phenylmethyl)-3-piperidinyl]methyl]amino]hexyl]-.beta.,.beta.-diphenyl- (9CI)

MF C40 H47 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus

AN 1995:849168 CAPLUS
 DN 123:285789
 TI Preparation of heterocyclyl carbamate derivatives with muscarine M3
 receptor antagonism
 IN Takeuchi, Makoto; Naito, Ryo; Morihira, Koichiro; Hayakawa, Masahiko;
 Ikeda, Ken; Isomura, Yasuo; Tomioka, Kenichi
 PA Yamanouchi Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 138 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9506635 | A1 | 19950309 | WO 1994-JP1436 | 19940831 |
| | W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9475458 | A1 | 19950322 | AU 1994-75458 | 19940831 |
| PRAI | JP 1993-218620 | | 19930902 | | |
| | JP 1994-77575 | | 19940415 | | |
| | WO 1994-JP1436 | | 19940831 | | |

OS MARPAT 123:285789

GI For diagram(s), see printed CA Issue.

AB Heterocyclyl (thio)carbamate and (thio)urea derivs. represented by general formula [I; R = (un)substituted aryl; R1 = cycloalkyl, (un)substituted aryl; R2 = H, OH, lower alkyl, lower alkoxy, cycloalkyl, aryl; R3 = H, lower alkyl; X = O, S; Y = O, S, (un)substituted NH, CH2, OCH2; ring A = heterocyclyl Q - Q1; wherein m, n = 1-4, provided that m + n = 3-5; l = 1-3, provided that m + l = 3-5; p, q = 0, 1; r, s, t = 0-3, provided that r + s + t = 2 or 3; Z = N(O)qR4, N+R5R6.Q-; Z1 = N(O)q, N+R6.Q-; wherein Q- = anion; R4 = H, lower alkyl, alkenyl, or alkynyl, B-R7; R5 = lower alkyl, alkenyl, or alkynyl, B-R7; R6 = lower alkyl, alkenyl, or alkynyl; wherein R7 = cycloalkyl, lower (hydroxy)alkoxy, benzhydryl, (un)substituted aryl, optionally benzene ring-fused or (un)substituted heterocyclyl contg. 1 or 2 heteroatoms; B = single bond, lower alkylene, alkenylene, or alkynylene] or salts, hydrates or solvates thereof are prepd. A muscarine M3 receptor antagonist for preventing or treating digestive tract, respiratory or urol. diseases such as irritable bowel syndrome, spasmodic colitis, diverticulitis, chronic obstructive lung diseases, chronic bronchitis, asthma, rhinitis, neural pollakiurea, nocturnal enuresis, nervous bladder, unstable bladder, bladder contracture, chronic cystitis, urinary incontinence, and pollakiurea, contains the said compd. I. Thus, 2.92 g NaBH(OAc)3 was added portion-wise to a soln. of 1.60 g 4-piperidyl N-benzhydrylcarbamate hydrochloride (prepn. given) and 0.40 mL 3-thiophenecarbaldehyde in 20 mL ClCH2CH2Cl and the resulting mixt. was stirred at room temp. overnight to give, after silica gel chromatog. and salt formation, a title compd. [II.(CO2H)2]. II.(CO2H)2 in vitro showed binding affinity to muscarine M1 receptor of cerebral cortex, muscarine M2 receptor of heart, and muscarine M3 receptor of submaxillary gland with Ki value of 1.0, 350, and 6.0 nM, resp., and Ki(M2 receptor)/Ki (M3 receptor) ratio of 58.

IT 168829-14-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of heterocyclyl (thio)carbamate derivs. as muscarine M3 receptor antagonists)

RN 168829-14-9 CAPLUS


CN Carbamic acid, (triphenylmethyl)-, 1-(phenylmethyl)-4-piperidinyl ester,

(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 168829-13-8

CMF C32 H32 N2 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



=> s (serine(1)protease) (1) (indol?(1)piperidin?)

86694 SERINE
73302 PROTEASE
85362 INDOL?
77850 PIPERIDIN?

L1 1 (SERINE(L)PROTEASE) (L) (INDOL?(L)PIPERIDIN?)

=> d bib

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

AN 2002:793361 CAPLUS

DN 137:310810

TI Preparation of indole and other fused heterocyclic inhibitors of factor Xa
useful for treating/preventing thromboembolic disorders

IN Jacobson, Irina C.; Quan, Mimi L.; Wexler, Ruth R.

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 149 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|--|----------|-----------------|----------|
| PI | WO 2002080853 | A2 | 20021017 | WO 2002-US10891 | 20020408 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| PRAI | US 2001-282438P | P | 20010409 | | |
| OS | MARPAT 137:310810 | | | | |

=> d abs

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

GI



AB This invention relates generally to a novel class of fused heterocyclic compds. (shown as I and II; e.g. 1-[[1-(3-fluoro-2'-methylsulfonyl)[1,1'-

biphenyl]-4-yl]-2-oxo-3-piperidinyl]-1H-indole
-6-carbonitrile) or pharmaceutically acceptable salt forms thereof, which are inhibitors of trypsin-like **serine protease** enzymes, esp. factor Xa, pharmaceutical compns. contg. the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders. Some compds. of this invention were evaluated and found to exhibit a K_i of $\leq 10^{-10}$ M, thereby confirming the utility of the compds. of the present invention as effective thrombin inhibitors. Although the methods of prepn. are not claimed, .apprx.15 example preps. are included. In I and II, ring D, including the two atoms of ring E to which it is attached, is a 5-6 membered nonarom. ring consisting of C atoms, 0-1 double bonds, and 0-2 heteroatoms N, O, and S(O)p, and ring D is substituted with 0-2 R1, provided that when ring D is unsubstituted, it consists of at least one heteroatom; alternatively, ring D, including the two atoms of ring E to which it is attached, is a 5-6 membered arom. system consisting of C atoms and 0-2 heteroatoms N, O, and S(O)p, and ring D is substituted with 0-2 R1, provided that when ring D is unsubstituted, it consists of at least one heteroatom. E is selected from Ph, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, and is substituted with 0-1 R1; alternatively, ring D is absent and ring E is selected from Ph, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, thienyl and triazolyl, and ring E is substituted with 0-2 Ra; Ra is selected from H, C1-4 alkyl, F, Cl, Br, I, OH, OCH3, OCH2CH3, OCH(CH3)2, OCH2CH2CH3, CN, C(:NR8)NR7R9, NHC(:NR8)NR7R9, NR8CH(:NR7), C(O)NR7R8, (CR8R9)tNR7R8, SH, SCH3, SCH2CH3, SCHMe2, SCH2CH2CH3, S(O)R3b, S(O)2R3a, S(O)2NR2R2a, and OCF3; alternatively, two Ras combine to form methylenedioxy or ethylenedioxy. Alternatively, ring D is absent and ring E is selected from Ph, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, and thienyl, and ring E is substituted with 1 R and with a 5-6 membered arom. heterocycle consisting of: C atoms and 1-4 heteroatoms N, O, and S(O)p substituted with 0-1 carbonyl groups and 0-2 R1. Ring F completes a 5-7 membered heterocycle consisting of C atoms, 1-3 heteroatoms N, NH, O, and -S(O)p-, 0-2 addnl. double bonds, and 0-2 carbonyl groups, provided that other than a O-O, O-S, or S-S bond is present in the ring and ring F is substituted with 0-1 R4c. Ring G completes a 5-7 membered nonarom. heterocycle consisting of C atoms, 1-3 heteroatoms N, NZ, O, and S(O)p, 0-2 double bonds, and 0-3 carbonyl groups, and ring G is substituted with 0-2 R1a, provided that other than a O-O, O-S, or S-S bond is present in ring G. Z is selected from H, S(O)2NHR3, C(O)R3, C(O)NHR3, C(O)OR3f, S(O)R3f, S(O)2R3f, C1-6 alkyl substituted with 0-2 R1a; C2-6 alkenyl substituted with 0-2 R1a; C2-6 alkynyl substituted with 0-2 R1a; -(C0-4 alkyl)-C3-10-carbocycle substituted with 0-3 R1a; -(C0-4 alkyl)-5-12 membered-heterocycle substituted with 0-3 R1a. G1 is selected from C, CH, and N; G2 is selected from CH, CH2, C(O), O, S(O)p, N, and NH; G3 is selected from C, CH, and N; A is selected from C3-10 carbocycle substituted with 0-2 R4, and 5-12 membered heterocycle consisting of C atoms and from 1-4 heteroatoms N, O, and S and substituted with 0-2 R4; B is selected from: Y, X-Y, (CH2)0-2C(O)NR2R2a, (CH2)0-2NR2R2a, C(:NR2)NR2R2a, and NR2C(:NR2)NR2R2a, provided that G3 and B are attached to different atoms on A. X is selected from -(CR2R2a)1-4-, -CR2(CR2R2b)(CH2)t-, -C(O)-, -C(:NR1c)-, -CR2(NR2R2a)-, -CR2(OR2)-, -CR2(SR2)-, -C(O)CR2R2a-, -CR2R2aC(O)-, -S-, -S(O)-, -S(O)2-, -SCR2R2a-, -S(O)CR2R2a-, -S(O)2CR2R2a-, -CR2R2aS-, -CR2R2aS(O)-, -CR2R2aS(O)2-, -S(O)2NR2-, -NR2S(O)2-, -NR2S(O)2CR2R2a-, -CR2R2aS(O)2NR2-, -NR2S(O)2NR2-, -C(O)NR2-, -NR2C(O)-, -C(O)NR2CR2R2a-, -NR2C(O)CR2R2a-, -CR2R2aC(O)NR2-, -CR2R2aNR2C(O)-, -NR2C(O)O-, -OC(O)NR2-, -NR2C(O)NR2-, -NR2-, -NR2CR2R2a-, -CR2R2aNR2-, O-, -CR2R2aO-, and -OCR2R2a-. Y is selected from -(CH2)rNR2R2a; C3-10 carbocycle substituted with 0-2 R4a; and 5-10 membered heterocycle consisting of C atoms and from 1-4 heteroatoms N, O, and S and substituted with 0-2 R4a; provided that X-Y do not form a N-N, O-N, or S-N bond; V is selected from C, CH, and N; U is a bond or is selected from CHR3b, C(O), O, S(O)p, NR3b, C(O)NR3, NR3C(O), C(O)CH2,

CH₂C(O), S(O)pNR₃, NR₃S(O)p, OCH₂, CH₂O, NR₃bCH₂, and CH₂NR₃b; provided that when ring D is absent, U is other than a bond; W is a bond or is selected from CHR₃b, C(O), O, S(O)p, NR₃b, C(O)NR₃, NR₃C(O), C(O)CH₂, CH₂C(O), S(O)pNR₃, NR₃S(O)p, OCH₂, CH₂O, NR₃bCH₂, and CH₂NR₃b; provided that when ring D is absent, W is a bond. Variables in I and II not defined above are defined in the claims.